Medicare Program; Virtual Meeting of the Medicare Evidence Development and Coverage Advisory Committee-May 21, 2024, 20656-20658 [2024-06148]

Agencies

• Centers for Medicare & Medicaid Services
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 89, Number 58 (Monday, March 25, 2024)]
[Notices]
[Pages 20656-20658]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-06148]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[CMS-3458-N]


Medicare Program; Virtual Meeting of the Medicare Evidence 
Development and Coverage Advisory Committee--May 21, 2024

AGENCY: Centers for Medicare & Medicaid Services (CMS), Health and 
Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice announces a virtual public meeting of the Medicare 
Evidence Development & Coverage Advisory Committee (MEDCAC) 
(``Committee'') will be held on Tuesday, May 21, 2024. The MEDCAC panel 
will consider which health outcomes in studies of devices for self-
management of Type 1 and insulin-dependent Type 2 diabetes should be of 
interest to CMS. Given the increased emphasis on new and innovative 
medical products for difficult to manage conditions, some studies of 
new medical technologies have focused on short-term data with greater 
reliance on intermediate outcomes and surrogate endpoints. As a result, 
assessments of new medical technologies have more frequent evidence 
gaps with respect to clinically meaningful health outcomes for CMS 
beneficiaries. The MEDCAC panel will examine the growing challenges 
associated with the decreased level of evidence of certain new and 
innovative technologies. By voting on specific questions, and by their 
discussions, MEDCAC panel members will advise CMS about the ideal 
health outcomes in

[[Page 20657]]

research studies of devices for diabetes self-management, appropriate 
measurement instruments and adequate follow-up durations to help to 
provide clarity and transparency in future National Coverage Analyses 
(NCAs). This meeting is open to the public in accordance with the 
Federal Advisory Committee Act (5 U.S.C. App. 2, section 10(a)).

DATES: 
    Meeting Date: The virtual meeting will be held on Tuesday, May 21, 
2024, from 10:00 a.m. until 4:00 p.m., Eastern Daylight Time (EDT).
    Deadline for Submission of Written Comments: Written comments must 
be received at the email address specified in the ADDRESSES section of 
this notice by 5:00 p.m., Eastern Daylight Time (EDT), on Monday, April 
22, 2024. Once submitted, all comments are final.
    Deadlines for Speaker Registration and Presentation Materials: The 
deadline to register to be a speaker and to submit PowerPoint 
presentation materials and writings that will be used in support of an 
oral presentation is 5:00 p.m., EDT, on Monday, April 22, 2024. 
Speakers may register via email by contacting the person listed in the 
FOR FURTHER INFORMATION CONTACT section of this notice. Presentation 
materials must be received at the email address specified in the 
ADDRESSES section of this notice.
    Submission of Presentations and Comments: Presentation materials 
and written comments that will be presented at the meeting must be 
submitted via email to [email protected] section of this 
notice by Monday, April 22, 2024.
    Deadline for All Other Attendees Registration: Individuals who want 
to join the meeting may register online at: https://cms.zoomgov.com/meeting/register/vJItcu6hpj4qHL_IlNFkPTSJOCXDvu2IiGg until May 21, 
2024, EDT at 10 a.m.
    Webinar and Teleconference Meeting Information: Teleconference 
dial-in instructions, and related webinar details will be posted on the 
meeting agenda, which will be available on the CMS website https://www.cms.gov/medicare-coverage-database/indexes/medcac-meetings-index.aspx?bc= BAAAAAAAAAAA&. Participants in the MEDCAC meeting will 
require the following: a computer, laptop or smartphone where the Zoom 
application needs to be downloaded; a strong Wi-Fi or an internet 
connection and access to use Chrome or Firefox web browser and a webcam 
if the meeting participant is scheduled to speak or make a presentation 
during the meeting.
    Deadline for Submitting a Request for Special Accommodations: 
Individuals viewing or listening to the meeting who are hearing or 
visually impaired and have special requirements, or a condition that 
requires special assistance, should send an email to the MEDCAC 
Coordinator as specified in the FOR FURTHER INFORMATION CONTACT section 
of this notice no later than 5:00 p.m., EDT on Friday, May 3, 2024.

ADDRESSES: To allow for broader public participation in the meeting, 
the Panel meeting will be held virtually.

FOR FURTHER INFORMATION CONTACT: Tara Hall, MEDCAC Coordinator, via 
email at [email protected] or by phone 410-786-4347.

SUPPLEMENTARY INFORMATION:

I. Background

    MEDCAC, formerly known as the Medicare Coverage Advisory Committee 
(MCAC), is advisory in nature, with all final coverage decisions 
resting with CMS. MEDCAC is used to supplement CMS' internal expertise. 
Accordingly, the advice rendered by the MEDCAC is most useful when it 
results from a process of full scientific inquiry and thoughtful 
discussion, in an open forum, with careful framing of recommendations 
and clear identification of the basis of those recommendations. MEDCAC 
members are valued for their background, education, and expertise in a 
wide variety of scientific, clinical, and other related fields. (For 
more information on MEDCAC, see the MEDCAC Charter (https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/Downloads/medcaccharter.pdf) and 
the CMS Guidance Document, Factors CMS Considers in Referring Topics to 
the MEDCAC (https://www.cms.gov/medicare-coverage-database/details/medicare-coverage-document-details.aspx?MCDId=10).

II. Meeting Topic and Format

    This notice announces the Tuesday, May 21, 2024, virtual public 
meeting of the Committee. The MEDCAC panel will examine what health 
outcomes in studies of devices for self-management of Type 1 and 
insulin-dependent Type 2 diabetes should be of interest to CMS. Given 
the increased emphasis on new and innovative medical products for 
difficult to manage conditions, some studies of new medical 
technologies have focused on short-term data with greater reliance on 
intermediate outcomes and surrogate endpoints. As a result, there are 
more frequent evidence gaps with respect to the clinically meaningful 
health outcomes for CMS beneficiaries in assessments of medical 
technologies. The MEDCAC panel will examine the growing challenges 
associated with the decreased level of evidence of certain new and 
innovative technologies. By voting on specific questions, and by their 
discussions, MEDCAC panel members will advise CMS about the ideal 
endpoints and health outcomes in research studies of devices for self-
management of Type 1 and insulin-dependent Type 2 diabetes, appropriate 
measurement instruments and follow-up durations to help to provide 
clarity and transparency of National Coverage Analyses (NCAs).
    Background information about this topic, including panel materials, 
is available at https://www.cms.gov/medicare-coverage-database/indexes/medcac-meetings-index.aspx?bc=BAAAAAAAAAAA&. Electronic copies of all 
the meeting materials will be on the CMS website approximately 30 days 
before the meeting. We encourage the participation of organizations 
with expertise in the appraisal of the state of evidence for the use of 
devices for self-management of Type 1 and insulin-dependent Type 2 
diabetes. This meeting is open to the public. The Committee will hear 
oral presentations from the public for approximately 45 minutes. Time 
allotted for each presentation may be limited, based on the number of 
speakers. If the number of registrants requesting to speak is greater 
than what can be reasonably accommodated during the scheduled open 
public hearing session, we may conduct a lottery to determine the 
speakers for the scheduled open public hearing session. The contact 
person will notify interested persons regarding their request to speak 
by May 7, 2024. Your comments must focus on issues specific to the list 
of topics that we have proposed to the Committee. The list of research 
topics to be discussed at the meeting will be available on the 
following website prior to the meeting: https://www.cms.gov/medicare-coverage-database/indexes/medcac-meetings-index.aspx?bc=BAAAAAAAAAAA&. 
We require that you declare at the meeting whether you have any 
financial involvement with manufacturers (or their competitors) of any 
items or services being discussed. Speakers presenting at the MEDCAC 
meeting must include a full disclosure slide as their second slide in 
their presentation for financial interests (for example, type of 
financial association--consultant, research support, advisory board, 
and an indication of level, such as minor association <$10,000 or major

[[Page 20658]]

association >$10,000) as well as intellectual conflicts of interest 
(for example, involvement in a federal or nonfederal advisory committee 
that has discussed the issue) that may pertain in any way to the 
subject of this meeting. If you are representing an organization, we 
require that you also disclose conflict of interest information for 
that organization. If you do not have a PowerPoint presentation, you 
will need to present the full disclosure information requested 
previously at the beginning of your statement to the Committee.
    The Committee will deliberate openly on the topics under 
consideration. Interested persons may observe the deliberations, but 
the Committee will not hear further comments during this time except at 
the request of the chairperson. The Committee will also allow a 15-
minute unscheduled open public session for any attendee to address 
issues specific to the topics under consideration. At the conclusion of 
the day, the members will vote, and the Committee will make its 
recommendation(s) to CMS.

III. Registration Instructions

    CMS' Coverage and Analysis Group is coordinating meeting 
registration. While there is no registration fee, individuals must 
register to attend. You may register online at https://cms.zoomgov.com/meeting/register/vJItcu6hpj4qHL_IlNFkPTSJOCXDvu2IiGg or by phone by 
contacting the person listed in the FOR FURTHER INFORMATION CONTACT 
section of this notice by the deadline listed in the DATES section of 
this notice. Please provide your full name (as it appears on your 
state-issued driver's license), address, organization, telephone 
number(s), and email address. You will receive a registration 
confirmation with instructions for your participation at the virtual 
public meeting.

IV. Collection of Information

    This document does not impose information collection requirements, 
that is, reporting, recordkeeping or third-party disclosure 
requirements. Consequently, there is no need for review by the Office 
of Management and Budget under the authority of the Paperwork Reduction 
Act of 1995 (44 U.S.C. Chapter 35).
    The Chief Medical Officer and Acting Director of the Center for 
Clinical Standards and Quality for the Centers for Medicare & Medicaid 
Services (CMS), Dora Hughes, having reviewed and approved this 
document, authorizes Chyana Woodyard, who is the Federal Register 
Liaison, to electronically sign this document for purposes of 
publication in the Federal Register.

Chyana Woodyard,
Federal Register Liaison, Centers for Medicare & Medicaid Services.
[FR Doc. 2024-06148 Filed 3-22-24; 8:45 am]
BILLING CODE 4120-01-P